Is PCVX or PTGX more profitable?

PTGX runs the higher net margin — PCVX at 0.00% versus PTGX at 29.40%.

How have PCVX and PTGX total returns compared?

Over the past 5 years, PCVX delivered 25.08% and PTGX delivered 50.88% annualized total return. Past performance doesn't predict future results.

Vaxcyte, Inc. (PCVX) vs Protagonist Therapeutics, Inc. (PTGX)

A side-by-side comparison of Vaxcyte, Inc. and Protagonist Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

PCVX

Vaxcyte, Inc.

$9.40B

$65.11HealthcareDelayed quote: Oct 6, 2026, 1:15 PM EDT

PTGX

Protagonist Therapeutics, Inc.

$8.81B

$136.97HealthcareDelayed quote: Oct 6, 2026, 1:15 PM EDT

Total return — PCVX vs PTGX

growth of $100 · dividends reinvested · last 6y

PCVX +182.3% (+18.9%/yr)PTGX +768.1% (+43.4%/yr)PTGX compounded faster over this window

PCVX PTGX

PCVX vs PTGX: by the numbers

•PCVX is the larger company ($9.40B vs $8.81B market cap).
•PTGX is profitable (29.40% net margin) while PCVX runs a net loss (0.00%).

Metrics side by side

Valuation

Metric	PCVX	PTGX
P/E ratio	N/A	132.50
P/S ratio	N/A	31.24
P/B ratio	3.41	10.47
EV / EBITDA	N/A	140.23
FCF yield	N/A	1.48%

Profitability

Metric	PCVX	PTGX
Gross margin	0.00%	99.86%
Operating margin	0.00%	-343.63%
Net margin	0.00%	29.40%
ROE	-38.59%	9.85%
ROIC	-40.65%	6.74%

Growth (annualized)

Metric	PCVX	PTGX
Revenue CAGR (5Y)	N/A	59.63%
Total return CAGR (5Y)	25.08%	50.88%

Frequently asked

Is PCVX or PTGX more profitable?: PTGX runs the higher net margin — PCVX at 0.00% versus PTGX at 29.40%.
How have PCVX and PTGX total returns compared?: Over the past 5 years, PCVX delivered 25.08% and PTGX delivered 50.88% annualized total return. Past performance doesn't predict future results.

Go deeper

Full PCVX analysis Full PTGX analysis Interactive comparison tool

Dig into the metrics

Protagonist Therapeutics P/E ratio Vaxcyte ROE Protagonist Therapeutics ROE Vaxcyte operating margin Protagonist Therapeutics operating margin Vaxcyte revenue growth Protagonist Therapeutics revenue growth Vaxcyte free cash flow Protagonist Therapeutics free cash flow

Vaxcyte & Protagonist Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.